NCT06505369 (TALTEC) is a Phase 2 clinical trial of Daratumumab in Multiple Myeloma, sponsored by North Estonia Medical Centre.

Who is sponsoring NCT06505369?

NCT06505369 is sponsored by North Estonia Medical Centre.

What drugs are being tested in NCT06505369?

Interventions in NCT06505369: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Talquetamab, Teclistamab.

What condition does NCT06505369 study?

NCT06505369 studies Multiple Myeloma.

Is NCT06505369 still recruiting?

NCT06505369 is currently recruiting now. Last updated 14 July 2024.

Last reviewed 2024-07-14 · How we verify

NCT06505369: TALTEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study Measuring MRD Negativity After Bispecific T-cell Redirectors Talquetamab and Teclistamab Consolidation in Sequence as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Recruiting now Phase 2 Last updated 14 July 2024

What this trial tests

Phase 2 trial testing Daratumumab in Multiple Myeloma in 50 participants. Currently enrolling.

Timeline

19 June 2024

Primary endpoint
1 November 2026

1 October 2028

Quick facts

Lead sponsor	North Estonia Medical Centre
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	19 June 2024
Primary completion	1 November 2026
Estimated completion	1 October 2028
Sites	7 locations across Denmark, Estonia, Norway

Drugs / interventions tested

Daratumumab
Bortezomib (bortezomib) — full drug profile →
Lenalidomide — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
Talquetamab
Teclistamab (TECLISTAMAB) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

North Estonia Medical Centre

Who can join

Adults 18 to 70, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Evaluate efficacy in terms of Minimal Residual Disease (MRD) negative Complete Remission rate by next generation sequencing ( NGS) after completing consolidation with talquetamab and teclistamab.
Time frame: 18 months approximately
MRD measured by NGS with a sensitivity level of 10-6.
Evaluate efficacy in terms of Minimal Residual Disease (MRD) negative Complete Remission rate by Fluorodeoxyglucose Positron Emission Tomography-Computerized Tomography (FDG PET-CT) scan after completing consolidation with talquetamab and teclistamab.
Time frame: 18 months approximately
MRD assessed by FDG PET-CT scan using Deauville score.

Sponsor's own description

This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy. The goal of the study is to determine if consolidation with T-cell redirectors - Talquetamab and Teclistamab in sequence will improve the response depth: increase MRD negative CR rate.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions.
Labanca C, Martino EA, Vigna E, Bruzzese A, et al · · 2025 · cited 14× · PMID 39604778 · DOI 10.1111/ejh.14353
Perspectives on Talquetamab and its Utility in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.
Miller KC, Hamadeh I, Tan CR. · · 2025 · PMID 40196851 · DOI 10.2147/cmar.s441550

Verify or expand the search:

Other trials of Daratumumab

Trials testing the same drug.

NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07393282 — A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) · Phase 3 · not yet recruiting
NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other North Estonia Medical Centre trials

Trials by the same sponsor.

NCT07490730 — Antegrade Transcystic Balloon Dilatation of the Papillary Sphincter During Emergency Laparoscopic Cholecystectomy for Co · completed
NCT05430633 — Laparoscopic Versus Open Appendectomy in Pregnancy · completed
NCT04947748 — Short Post-operative Antibacterial Therapy in Complicated Appendicitis: Oral Versus Intravenous · NA · unknown
NCT05479227 — Bile Duct Injuries During Laparoscopic Cholecystectomies: An 11-year Population-based Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06505369 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by North Estonia Medical Centre
Last refreshed: 14 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06505369.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing